|Single-strand specificity of APOBEC3G accounts for minus-strand deamination of the HIV genome|
Q Yu, R König, S Pillai, K Chiles, M Kearney, S Palmer, D Richman, ...
Nature structural & molecular biology 11 (5), 435-442, 2004
|Low-level viremia persists for at least 7 years in patients on suppressive antiretroviral therapy|
S Palmer, F Maldarelli, A Wiegand, B Bernstein, GJ Hanna, SC Brun, ...
Proceedings of the National Academy of Sciences 105 (10), 3879-3884, 2008
|Depletion of latent HIV-1 infection in vivo: a proof-of-concept study|
G Lehrman, IB Hogue, S Palmer, C Jennings, CA Spina, A Wiegand, ...
The Lancet 366 (9485), 549-555, 2005
|New real-time reverse transcriptase-initiated PCR assay with single-copy sensitivity for human immunodeficiency virus type 1 RNA in plasma|
S Palmer, AP Wiegand, F Maldarelli, H Bazmi, JAM Mican, M Polis, ...
Journal of clinical microbiology 41 (10), 4531-4536, 2003
|HIV-1 replication and immune dynamics are affected by raltegravir intensification of HAART-suppressed subjects|
MJ Buzón, M Massanella, JM Llibre, A Esteve, V Dahl, MC Puertas, ...
Nature medicine 16 (4), 460, 2010
|Upregulation of CTLA-4 by HIV-specific CD4+ T cells correlates with disease progression and defines a reversible immune dysfunction|
DE Kaufmann, DG Kavanagh, F Pereyra, JJ Zaunders, EW Mackey, ...
Nature immunology 8 (11), 1246-1254, 2007
|Multiple, linked human immunodeficiency virus type 1 drug resistance mutations in treatment-experienced patients are missed by standard genotype analysis|
S Palmer, M Kearney, F Maldarelli, EK Halvas, CJ Bixby, H Bazmi, D Rock, ...
Journal of clinical microbiology 43 (1), 406-413, 2005
|Lytic granule loading of CD8+ T cells is required for HIV-infected cell elimination associated with immune control|
SA Migueles, CM Osborne, C Royce, AA Compton, RP Joshi, KA Weeks, ...
Immunity 29 (6), 1009-1021, 2008
|Towards an HIV cure: a global scientific strategy|
SG Deeks, B Autran, B Berkhout, M Benkirane, S Cairns, N Chomont, ...
Nature reviews Immunology 12 (8), 607, 2012
|Treatment intensification does not reduce residual HIV-1 viremia in patients on highly active antiretroviral therapy|
JB Dinoso, SY Kim, AM Wiegand, SE Palmer, SJ Gange, L Cranmer, ...
Proceedings of the National Academy of Sciences 106 (23), 9403-9408, 2009
|Comparative analysis of measures of viral reservoirs in HIV-1 eradication studies|
S Eriksson, EH Graf, V Dahl, MC Strain, SA Yukl, ES Lysenko, RJ Bosch, ...
PLoS pathogens 9 (2), 2013
|Panobinostat, a histone deacetylase inhibitor, for latent-virus reactivation in HIV-infected patients on suppressive antiretroviral therapy: a phase 1/2, single group, clinical …|
TA Rasmussen, M Tolstrup, CR Brinkmann, R Olesen, C Erikstrup, ...
The lancet HIV 1 (1), e13-e21, 2014
|ART suppresses plasma HIV-1 RNA to a stable set point predicted by pretherapy viremia|
F Maldarelli, S Palmer, MS King, A Wiegand, MA Polis, JA Mican, ...
PLoS pathogens 3 (4), 2007
|Activation of HIV transcription with short-course vorinostat in HIV-infected patients on suppressive antiretroviral therapy|
JH Elliott, F Wightman, A Solomon, K Ghneim, J Ahlers, MJ Cameron, ...
PLoS pathogens 10 (11), 2014
|The effect of raltegravir intensification on low-level residual viremia in HIV-infected patients on antiretroviral therapy: a randomized controlled trial|
RT Gandhi, L Zheng, RJ Bosch, ES Chan, DM Margolis, S Read, ...
PLoS medicine 7 (8), 2010
|Challenges in detecting HIV persistence during potentially curative interventions: a study of the Berlin patient|
SA Yukl, E Boritz, M Busch, C Bentsen, TW Chun, D Douek, E Eisele, ...
PLoS pathogens 9 (5), 2013
|International AIDS Society global scientific strategy: towards an HIV cure 2016|
SG Deeks, SR Lewin, AL Ross, J Ananworanich, M Benkirane, P Cannon, ...
Nature medicine 22 (8), 839, 2016
|Multiple concurrent reverse transcriptase and protease mutations and multidrug resistance of HIV-1 isolates from heavily treated patients|
RW Shafer, MA Winters, S Palmer, TC Merigan
Annals of Internal Medicine 128 (11), 906-911, 1998
|Short-course raltegravir intensification does not reduce persistent low-level viremia in patients with HIV-1 suppression during receipt of combination antiretroviral therapy|
D McMahon, J Jones, A Wiegand, SJ Gange, M Kearney, S Palmer, ...
Clinical infectious diseases 50 (6), 912-919, 2010
|A Randomized, Controlled Trial of Raltegravir Intensification in Antiretroviral-treated, HIV-infected Patients with a Suboptimal CD4+ T Cell Response|
H Hatano, TL Hayes, V Dahl, E Sinclair, TH Lee, R Hoh, H Lampiris, ...
The Journal of infectious diseases 203 (7), 960-968, 2011